Episode
HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer
- Published
- Jun 17, 2026
- Duration seconds
- 5279
- Processing state
not_requested- Canonical source
- https://oncologytoday.captivate.fm/episode/5833-sgo26her2gyn
Actions
POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/her2-positive-gynecologic-cancers-proceedings-from-a-session-held-during-the-society-of-gynecologic-oncology-2026-annual-meeting-on-women-s-cancer/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/her2-positive-gynecologic-cancers-proceedings-from-a-session-held-during-the-society-of-gynecologic-oncology-2026-annual-meeting-on-women-s-cancer.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley and Dr Brian M Slomovitz, moderated by Dr O’Malley, including the following topics: Introduction (0:00) Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52) Available Data with and Practical Application of HER2-Targeted Therapy in Advanced Gynecologic Cancers — Dr Slomovitz (25:16) Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr O’Malley (1:00:31) CME information and select publications